KRAS and pancreatic adenocarcinoma: Instead, there was barely any difference (P=0.6427) of OS between the patients with co-occurrence of KRAS G12D and TP53 mutations or not in a metastatic PAAD cohort24 (N=293) (Supplementary Fig. S9E, Supplemental Digital Content 3, http://links.lww.com/JS9/A234), which was similar to our observation that HLA-A02+B62+B44− failed to stratify in stage III patients with PAAD (Supplementary Fig. S1B, Supplemental Digital Content 3, http://links.lww.com/JS9/A234).